عرض بسيط للتسجيلة

المؤلفAl-Badriyeh, Daoud
المؤلفFahey, Michael
المؤلفAlabbadi, Ibrahim
المؤلفAl-Khal, Abdullatif
المؤلفZaidan, Manal
تاريخ الإتاحة2024-04-30T05:47:44Z
تاريخ النشر2015
اسم المنشورClinical Therapeutics
المصدرScopus
المعرّفhttp://dx.doi.org/10.1016/j.clinthera.2015.07.020
الرقم المعياري الدولي للكتاب1492918
معرّف المصادر الموحدhttp://hdl.handle.net/10576/54472
الملخصPurpose Statin selection for the largest hospital formulary in Qatar is not systematic, not comparative, and does not consider the multi-indication nature of statins. There are no reports in the literature of multi-indication-based comparative scoring models of statins or of statin selection criteria weights that are based primarily on local clinicians' preferences and experiences. This study sought to comparatively evaluate statins for first-line therapy in Qatar, and to quantify the economic impact of this. Methods An evidence-based, multi-indication, multi-criteria pharmacotherapeutic model was developed for the scoring of statins from the perspective of the main health care provider in Qatar. The literature and an expert panel informed the selection criteria of statins. Relative weighting of selection criteria was based on the input of the relevant local clinician population. Statins were comparatively scored based on literature evidence, with those exceeding a defined scoring threshold being recommended for use. Findings With 95% CI and 5% margin of error, the scoring model was successfully developed. Selection criteria comprised 28 subcriteria under the following main criteria: clinical efficacy, best publish evidence and experience, adverse effects, drug interaction, dosing time, and fixed dose combination availability. Outcome measures for multiple indications were related to effects on LDL cholesterol, HDL cholesterol, triglyceride, total cholesterol, and C-reactive protein. Atorvastatin, pravastatin, and rosuvastatin exceeded defined pharmacotherapeutic thresholds. Atorvastatin and pravastatin were recommended as first-line use and rosuvastatin as a nonformulary alternative. It was estimated that this would produce a 17.6% cost savings in statins expenditure. Sensitivity analyses confirmed the robustness of the evaluation's outcomes against input uncertainties. Implications Incorporating a comparative evaluation of statins in Qatari practices based on a locally developed, transparent, multi-indication, multi-criteria scoring model has the potential to considerably reduce expenditures on statins. Atorvastatin and pravastatin should be the first-line statin therapies in the main Qatari health care provider, with rosuvastatin as an alternative.
راعي المشروعThis work was supported by the National Priority Research Programme, Qatar National Research Fund (NPRP-5-284-3-083), Qatar Foundation, Doha, Qatar. The study did not receive funding or sponsorship from any pharmaceutical industry. The authors would like to thank Ms. Rula Shami, BPharm, Research Assistant, College of Pharmacy, Qatar University, Qatar, for the support she provided in this project. Dr. Al-Badriyeh conducted the literature review and manuscript writing, and is the mostly responsible for the study design and the data collection and interpretation. All co-authors meet the criteria for authorship set by the International Committee for Medical Journal Editors. All authors reviewed and approved the manuscript version as submitted.
اللغةen
الناشرElsevier
الموضوعmulti-criteria
multi-indication
Qatar
scoring model
selection
statins
العنوانStatin Selection in Qatar Based on Multi-indication Pharmacotherapeutic Multi-criteria Scoring Model, and Clinician Preference
النوعArticle
الصفحات2798-2810
رقم العدد12
رقم المجلد37
dc.accessType Abstract Only


الملفات في هذه التسجيلة

الملفاتالحجمالصيغةالعرض

لا توجد ملفات لها صلة بهذه التسجيلة.

هذه التسجيلة تظهر في المجموعات التالية

عرض بسيط للتسجيلة